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Abstract
Background: Otosclerosis is characterized by bony deposits in the otic capsule, resulting in stapes fixation and
progressive hearing loss. It can be treated effectively by surgically removing (part of) the stapes and replacing it
with a prosthesis. Increasingly, stapes surgery is performed as a day-case procedure. The major drive towards
day-case surgery has been out of economic considerations. However, it is also increasingly an explicit patient
request and leads to shorter waiting times for surgery, a reduced risk of infection and most likely positively
influences the patient’s quality of life as a result of rapid discharge and rehabilitation. Even though stapes surgery
seems well suited to a day-case approach, given the low complication rates and early recovery, evidence is scarce
and of low quality.
Methods and design: A single-center unblinded randomized controlled trial was designed to (primarily)
investigate the effect of hearing outcomes of day-case stapes surgery compared to inpatient stapes surgery
and (secondarily) investigate the effect of both methods on quality of life, tinnitus, vertigo and cost-
effectiveness. One hundred and twelve adult otosclerosis patients who are eligible for stapes surgery will be
randomly assigned to either the day-case or inpatient treatment group. The primary and secondary outcome
measures will be assessed using pure-tone audiometry (at approximately 2 months and 1 year follow-up),
questionnaires (at 3 months and 1 year follow-up) and costs diaries (weekly the first month after which once
a month until 1 year follow-up).
Discussion/conclusion: This trial allows for a comparison between day-case and inpatient stapes surgery to
investigate the hypothesis that day-case stapes surgery is associated with a higher quality of life and higher
cost-effectiveness, while maintaining equal hearing results, compared to inpatient stapes surgery.
Trial registration: Netherlands Trial Register (www.trialregister.nl): NTR4133, registration date 21st August 2013.
Keywords: Otosclerosis, Stapedotomy, Day-case, Inpatient, Hearing loss, Hearing results, Audiometry, Tinnitus,
Vertigo, Quality of life
Background
Otosclerosis is characterized by abnormal sponge-like
bone growth in the otic capsule, causing progressive
hearing loss, vertigo and/or tinnitus [1]. It mainly affects
the ossicular chain and can be treated surgically by re-
moving (part of ) the stapes and replacing it with a
prosthesis; stapedotomy and stapedectomy respectively.
Numerous surgeons have reported either equal hearing
results when comparing stapedotomy and stapedectomy
or better results with stapedotomy [2–6]. Although
stapes surgery has proven to be a safe and effective treat-
ment option for otosclerosis [7], permanent sensori-
neural hearing loss can occur and is the most dreaded
complication of stapes surgery. The incidence of this
complication following primary stapes surgery has
been reported to be less than 1 % in large series [8, 9].
Other complications associated with stapes surgery are
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postoperative vertigo in 12-45 % of patients [10–13] and
tinnitus in 8-54 % of patients [14–17].
Currently, in our clinic, stapes surgery involves over-
night hospital stay. Many other otologic procedures that
involved overnight hospital stay in the past are presently
being performed on an outpatient basis successfully
[18–20]. Ear, nose and throat (ENT) surgery is well
suited to a day-case approach as many of the disease en-
tities are benign and procedures are associated with low
complication rates [18]. Even though one of the major
drives towards day-case surgery has been financial, other
non-financial benefits are of major importance. Day-case
surgery is associated with shorter waiting time for sur-
gery and reduced risk of infection [21]. Moreover, as a
result of a more rapid social and emotional rehabilitation
compared to overnight stay, patients might prefer day-
case surgery.
Reports on day-case surgery for otosclerosis are scarce
[22, 23]. One prospective case series of 24 consecutive
otosclerosis patients undergoing day-case stapes surgery
[22] reported a readmission rate of 12.5 percent, reasons
being vertigo and asthenia. All of these patients were
treated under general anesthesia. One prospective case-
control study comparing ten day-case and ten inpatient
stapedectomies [23] showed no difference in postopera-
tive hearing thresholds, sensorineural hearing loss,
speech audiometry or postoperative vertigo. All proce-
dures were performed under local anesthesia. The au-
thors did not report on quality of life (QoL) following
day-case surgery.
The lack of (high-quality) studies precludes firm
evidence-based recommendations and demonstrates the
need for high-quality studies quantifying the benefits of
day-case surgery, both clinical and financial. In order to
accommodate this need, in this study we shall compare
day-case stapes surgery to inpatient stapes surgery. The
study will be conducted as a randomized controlled trial.
Methods and design
This protocol is reported according to the SPIRIT State-
ment, an international guideline on reporting protocols [24].
Study objectives
The primary objective of this study is to evaluate
effectiveness of day-case stapes surgery compared to in-
hospital stapes surgery followed by one-day hospital
admittance for otosclerosis, in terms of hearing improve-
ment. In addition, subjective participants’ perception on
hearing improvement, QoL, tinnitus, vertigo and cost-
effectiveness will be assessed.
Study design
The study design will be a single-center, unblinded, ran-
domized controlled trial. Subjects will be assigned to one
of two groups: day-case surgery under general anesthesia
or inpatient stapes surgery under general anesthesia
followed by one-day hospital admittance (Fig. 1).
Study population
The study population consists of adults with otoscler-
osis, as diagnosed in the outpatient clinic of the ENT
department at the University Medical Center Utrecht
(UMC Utrecht), the Netherlands, who will be undergo-
ing (revision) stapedotomy. In order to be eligible to
participate in this study, a subject must meet all of the
following criteria:
Inclusion criteria
– Age ≥ 18.
– Otosclerosis based on a clinical history of
progressive hearing loss and pure-tone audiometry
showing conductive hearing loss with an air-bone
gap > 20 dB above normal adult hearing level and a
perceptive hearing loss < 35 dB above normal adult
hearing level in the range of 500, 1000, 2000 and
4000 Hz.
– Willingness and ability to participate in all scheduled
procedures outlined in the research protocol.
– General health allowing general anesthesia in an
outpatient setting as assessed by an anesthesiologist.
– Quick access to communication and transportation
in case of any complications.
– Good understanding of the Dutch language.
A potential subject who meets any of the following cri-
teria will be excluded from participation in this study:
Exclusion criteria
– Previous middle ear surgery other than previous
middle ear inspection or stapes surgery;
– Known aberrant (middle ear) anatomy in one or
both ears based on a clinical history, otologic
examination, imaging and/or previous middle ear
inspection and assessed by an ENT surgeon;
– Co-morbid middle or inner ear pathology based on
a clinical history, otologic examination, imaging
and/or previous middle ear inspection and assessed
by an ENT surgeon, including osteogenesis imperfect
or an active ear infection in one or both ears;
– Disability that could interfere with audiologic
evaluation and/or questionnaire fulfillment.
Sample size calculation and recruitment
To establish equivalence in postoperative mean air con-
duction of 5 dB (standard deviation 10) between the
day-case and the inpatient group with an alpha of 0.05
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Fig. 1 Flow diagram of Day-case stapes surgery study. Abbreviations: RCT = Randomized Controlled Trial, TBQ = Tinnitus Burden Questionnaire,
VBQ = Vertigo Burden Questionnaire
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and a power of 80 %, 51 participants per group are
needed. To anticipate on a withdrawal of 10 % of the
participants, 5 more participants than needed will be
recruited per group. At the ENT department in UMC
Utrecht, we perform an average of 80 (revision) stapedo-
tomies per year. Assuming a participation rate of 75 %,
we will be able to include the necessary number of 112
patients in two years. If participants wish to leave the
study or the investigator decides to withdraw a partici-
pant from the study for urgent medical reasons, these
participants will not be replaced unless these account for
more than 10 %.
Patients will be recruited from the outpatient ENT de-
partment of the UMC Utrecht. If an otosclerosis patient
meets the criteria for stapes surgery and the inclusion
criteria for this study, one of the researchers will explain
the content of the study and provide the patient with
written patient information and an informed consent
form. Patients consent to the use of their data for the re-
search purposes outlined in this protocol, which includes
publication of the results once the trial has been com-
pleted. Further details can be found in Additional file 1
(informed consent form; translated to English, original
in Dutch). Patients that do not want to be included in
the study because they want to undergo stapes surgery
in a clinical setting will be asked whether they want to
fulfill the study procedures and whether their data can
be used for analysis.
Randomization, blinding and treatment allocation
A web-based randomization program (Julius Center,
UMC Utrecht, Utrecht, The Netherlands) shall be used
to allocate subjects randomly into two groups with
stratification for age. Block randomization will be used
with an allocation ratio of 1:1. The randomization chart,
including block size, is established before the start of the
study by an independent data manager and will not be
available to any of the people involved with enrolment
or treatment of participants. Consequently, treatment al-
location sequence is concealed for participants, care pro-
viders and researchers. Blinding of both participants and
care providers is not possible, since both participants
and care providers will be aware of the surgical setting
and hospital stay.
Intervention
The surgical procedures, as well as hospitalization in the
inpatient group, will take place at the UMC Utrecht. Pa-
tients in both groups will undergo (revision) stapedot-
omy under general anesthesia. The surgical procedure
will be performed by three surgeons according to stand-
ard protocol in the UMC Utrecht [7].
Patients allocated to the conventional group will be
admitted one day before or the day of surgery and will
be discharged one day after surgery. Patients allocated
to the day-case group will be admitted into the out-
patient unit one day before or on the day of the sur-
gery and will be discharged the day of the surgery.
Patients are not allowed to drive for 24 h following
day-case surgery and will be recommended 24 h of
relative bed rest. After a period of 24 h, patients can
return to their daily routine. Participants will be
asked to contact the hospital in case of severe post-
operative vertigo or pain. The ear tampon will be re-
moved in the outpatient clinic seven to ten days
postoperatively in both groups.
It is to be expected that patients who have been oper-
ated on in day-case will sometimes stay overnight, for
example due to postoperative nausea or dizziness. If pa-
tients are not physically capable of same-day discharge
or if surgeons do not support this, patients will stay
overnight. These patients will be asked to complete their
follow-up and analyses will be carried out on an
intention-to-treat basis.
Outcome measures
Evaluation will take place preoperatively and at ap-
proximately two months, three months and one year
postoperatively by means of pure-tone audiometry,
speech audiometry and questionnaires. Vertigo and
tinnitus will also be evaluated directly postoperatively.
In addition participants will be asked to keep a costs
diary for the duration of one year. Questionnaires and
costs diaries can be fulfilled digitally or on paper and
will be sent via email or mail respectively.
Primary outcome measure
Our primary outcome is the postoperative air conduc-
tion at approximately two and twelve months postopera-
tively, as measured by pure-tone audiometry for the
following frequencies: 500, 1000, 2000 and 4000 Hz, in
accordance with the Committee on Hearing and
Equilibrium guidelines for the evaluation of results of
treatment of conductive hearing loss [25]. However,
thresholds at 3000 Hz were substituted in all cases
with those at 4000 Hz, because the 3000 Hz fre-
quency is not part of the standard measurement
protocol in the Netherlands.
Secondary outcome measures
Our secondary outcome measures include (subjective)
hearing improvement, patient satisfaction, QoL, tinntus,
vertigo and cost-effectiveness.
Pure-tone and speech audiometry
Pure-tone and speech audiometry will be performed pre-
operatively and at approximately two and twelve months
postoperatively. Measurements will include mean four-
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frequency bone conduction thresholds, air conduction
thresholds and air-bone gap. The following frequencies
will be used to calculate mean thresholds: 500, 1000,
2000 and 4000 Hz. Sensorineural hearing loss will be
evaluated using frequencies 1000, 2000 and 4000 Hz.
Sensorineural hearing loss is defined as a deterioration
in mean bone conduction thresholds exceeding 10 to
15 dB.
Performance on speech audiometry will provide infor-
mation on word recognition abilities and can, in con-
junction with pure-tone audiometry, help determine the
degree and type of hearing loss.
Patient satisfaction
Patient satisfaction will be evaluated using the Utrecht
patient satisfaction survey (Additional file 2; translated
to English, original in Dutch). This seven-item question-
naire was developed in our center and contains ques-
tions regarding the hospital stay. Specifically patients are
asked whether they were satisfied with the intervention
group that they were allocated to.
Quality of life
QoL and hearing benefit will be assessed preoperatively
and at three and twelve months postoperatively using
the following four questionnaires:
- The Glasgow Health Status Inventory questionnaire:
an 18-item questionnaire, which measures the effect
of an otologic problem on QoL at the time the
questionnaire is completed. Three domains (general,
social support and physical health) are measured
based on a 5-point Likert scale ranging from high
health status to low health status. The total score
ranges from 0 to +100.
- Glasgow Benefit Inventory: an 18-item questionnaire,
which measures the change in health status as a result
of a surgical intervention. A specific version of the
Glasgow Benefit Inventory will be used that has been
validated to measure changes in health status as a
result of otorhinolaryngological procedures [26]. The
same three domains as the Glasgow Health Status
Inventory questionnaire are measured according to
the 5-point Likert scale. The total score ranges from
-100 (maximal negative benefit), through 0 (no
benefit), to +100 (maximum benefit).
- EuroQoL-5D: a five-item questionnaire on mobility,
self-care, daily activities, pain and complaints and
anxiety or depression that assesses general health
status [27, 28]. In addition, the general health
status is rated on a visual analogue scale than runs
from 0 to 10. A score of 0 equals worst imaginable
health state and a score of 10 equals best
imaginable health state.
- Health Utilities Index 3: a fifteen-item questionnaire
that measures general health status by evaluating
eight domains: vision, hearing, speech, ambulation,
dexterity, cognition, emotion and pain [29].
Tinnitus and vertigo
Tinnitus and vertigo will be assessed preoperatively and
at three and twelve months postoperatively using the
following four questionnaires. The Utrecht Burden
Questionnaire for tinnitus and vertigo will also be ad-
ministered directly postoperatively in case of direct post-
operative tinnitus and/or vertigo:
– Tinnitus Handicap Inventory: a 25-item questionnaire
evaluating three domains: a functional, emotional and
catastrophic domain [30, 31];
– Tinnitus Questionnaire: a 52-item questionnaire
evaluating five domains: tinnitus-related emotional
and cognitive distress, intrusiveness, auditory
perceptual difficulties, sleep disturbance and somatic
complaints. The response categories are ‘true’
(0/2 points), ‘partly true’ (1 point) and ‘not true’
(0/2 points), depending on the question. A validated
Dutch version will be used [32, 33];
– Dizziness Handicap Inventory: a 25-item questionnaire
evaluating three domains: functional, emotional, and
physical aspects of dizziness and unsteadiness. The
response categories are ‘yes’ (4 points), ‘sometimes’
(2 points), and ‘no’ (0 points). The total score
discriminates between a mild (16–34 points),
moderate (36–52 points), and severe (54+ points)
handicap. A validated Dutch version will be used
[34, 35];
– Utrecht Burden Questionnaire for tinnitus and
vertigo: measures severity and character of tinnitus
and vertigo by using visual analogue scales and
numerical rating scales (Additional file 3).
Cost-effectiveness/utility analysis
The difference in costs and benefit will be represented
using the Incremental Cost Utility/Effectiveness Ratio
(ICUR/ICER). The ICUR/ICER is calculated by dividing
the difference in costs by the difference in utility or ef-
fectiveness. Effectiveness will be reflected by pure-tone
audiometric results. Utility reflects the amount of money
that people are willing to pay to achieve a certain health
status. Utility scores derived from questionnaires such as
the EuroQoL-5D and the Health Utilities Index 3 can be
used to calculate the ICUR.
Participants will be asked to keep a costs diary. Partici-
pants will fulfill this diary preoperatively and at regular
intervals postoperatively. The first month the diary will
be fulfilled weekly followed by monthly fulfillment for
the duration of one year. Costs will be measured from a
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societal and health care perspective. Both direct and in-
direct costs will be collected. Direct costs include
hospitalization, surgery, doctor’s visits, and diagnostic
tests. Indirect costs include travel expenses and sick
leave. The Dutch guidelines for costing research in
health economic evaluations, issued by the National
Healthcare Institute [36], will be used to calculate unit
prices of resources that were used.
Statistical analysis
Baseline characteristics per group will be described as
means and standard deviations. Differences in the base-
line will be analyzed using the independent samples
students t-test or non-parametric tests for continuous
variables and the Fisher’s exact test for categorical
variables.
The primary and secondary outcome data are quanti-
tative and will be presented both continuous and cat-
egorical. Between-group mean differences, rate
differences and rate ratios with 95 % confidence intervals
will be calculated. For further analysis of between-group
differences in both primary and secondary outcomes the
independent samples students t–test or non-parametric
tests will be used for continuous outcomes and the Fish-
er’s exact test for categorical outcomes. Within-subject
comparisons will entail differences in mean values and
percentages before and after stapes surgery. These will
be analyzed using paired t-tests for continuous measures
and the McNemar test for categorical outcomes.
Missing values will be handled using multiple imput-
ation and all analyses will be performed on an intention-
to-treat basis. A sensitivity analysis will be performed
using all of the data acquired from patients that opted
not to be included in the study, but did fill out the ques-
tionnaires and underwent pure-tone audiometric and
speech audiometric follow-up.
The data will be reported according to the CONSORT
Statement [37, 38].
Safety reporting, ethics and funding
The study will be conducted according to the principles
of the Declaration of Helsinki (Fortaleza, 2013) and in
accordance with the Medical Research Involving Human
Subjects Act (WMO). The study will be funded by the
UMC Utrecht. As such it was peer reviewed by the
funding organization. This research protocol was ap-
proved by the Institutional Review Board of the UMC
Utrecht (NL45219.041.13; version 3, March 2015). The
approved research protocol can be found online in the
Netherlands Trial Register (www.trialregister.nl): NTR4133,
registration date 21st August 2013.
All cases of serious adverse events will be reported to
the local Institutional Review Board and adequately
followed up. An independent monitor is appointed to
check trial quality (completeness of informed consent
forms, validity of data, etc.) once a year. All data will be
handled confidentially. The data will be analysed an-
onymously by using a unique patient identification num-
ber. The investigator will safeguard the key to the code.
The primary source of the data will be paper files, which
will be stored in a locked room. The data will be stored
on the investigator’s computer as well, which is secured
by a password and located in a locked room.
Trial status
The trial is currently in recruitment phase.
Discussion/conclusion
Stapes surgery seems to be a surgical procedure that is
well suited for day-case treatment as it has proven to be
a safe treatment with low complication rates. However,
current literature lacks evidence based recommendations
supporting day-case stapes surgery. This randomized
controlled trial allows for a comparison between day-
case and inpatient stapes surgery to investigate the
hypothesis that day-case stapes surgery is associated
with a higher QoL and higher cost-effectiveness, while
maintaining equal hearing results, compared to inpatient
stapes surgery. This is the first high quality trial evaluat-
ing and quantifying the benefits of day-case stapes
surgery for patients with otosclerosis.
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